Mereo BioPharma Q3 net loss narrows aided by foreign currency gain

Mereo BioPharma

10/11/2025 21:12

Overview

Mereo BioPharma Q3 net loss narrows to $7 mln, aided by foreign currency gain

Company's cash reserves of $48.7 mln expected to support operations into 2027

Outlook

Mereo's cash reserves expected to support operations into 2027

Result Drivers

SETRUSUMAB INVESTMENT - Increased R&D expenses for setrusumab driven by manufacturing and supply agreements with Ultragenyx and pre-commercial activities in Europe

ALVELESTAT PREPARATION - R&D expenses for alvelestat rose due to Phase 3 study preparations, including drug product and packaging

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$7.02 mln
Q3 Operating Income
-$10.0 mln
Q3 Pretax Profit
-$7.02 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $7.00, about 74.3% above its November 7 closing price of $1.80

Press Release: ID:nGNXjCTcJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)